Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12385388 | 0.70 | ATR (0.37) | ALDH1A1MAPTNPC1RAB9AHTR2A | |
| SCHEMBL2301208 | 0.69 | ALDH1A1 (0.41) | ALDH1A1MAPTHTTKDM4ENPC1 | |
| SCHEMBL2302107 | 0.68 | AKT1 (0.40) | ALDH1A1MAPTSLC13A5KDM4ENPC1 | |
| SCHEMBL1529584 | 0.63 | ALDH1A1 (0.47) | ALDH1A1MAPTHTTKDM4ENPC1 | |
| SCHEMBL15392854 | 0.61 | ALDH1A1 (0.58) | ALDH1A1MAPTHTTNPC1RAB9A | |
| SCHEMBL2303639 | 0.60 | AKT1 (0.39) | ALDH1A1MAPTKDM4ENPC1LMNA | |
| SCHEMBL1529625 | 0.60 | HTR2A (0.46) | ALDH1A1MAPTNPC1HTR2AHTR2C | |
| SCHEMBL1529928 | 0.60 | DAO (0.44) | ALDH1A1MAPTHTTKDM4ENPC1 | |
| SCHEMBL16652413 | 0.59 | CYP3A4 (0.45) | ALDH1A1MAPTKDM4ENPC1LMNA | |
| SCHEMBL5307793 | 0.59 | PTGS2 (0.38) | ALDH1A1MAPTHTTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592475-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196009-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ALDH1A1 3652/4885MAPT 4189/4885ITGB1 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.